Targeted therapies for CLL: Practical issues with the changing treatment paradigm
- 23 December 2015
- journal article
- review article
- Published by Elsevier BV in Blood Reviews
- Vol. 30 (3), 233-244
- https://doi.org/10.1016/j.blre.2015.12.002
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaThe New England Journal of Medicine, 2013
- The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cellsLeukemia, 2012
- Tetraspanin CD37 Directly Mediates Transduction of Survival and Apoptotic SignalsCancer Cell, 2012
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemiasBlood, 2011
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid LeukemiaThe New England Journal of Medicine, 2011
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaBlood, 2009
- Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibodyBlood, 2009
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemiaBlood, 2006